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Abstract
Background: To exam the biochemical, obstetric management and pregnancy outcome in women with
intrahepatic cholestasis of pregnancy (ICP) and treatment with ursodeoxycholic acid (UDCA).
Methods: Pregnancy outcome in patients with ICP (N = 307) was studied and patients treated with UDCA (N = 208)
vs. no UDCA were compared. The data of the antenatal visits, deliveries and neonatal outcome of 307 pregnancies
with ICP was collected from the hospital computerized delivery room log book. UDCA was used in 208 pregnancies.
The diagnosis was made by maternal pruritus and elevation of total fasting bile acid (BA) (>6 μmol/l) and elevation of
serum alanine aminotransferases (ALT) (>45 U/l). Maternal and neonatal data was analysed and data of the patients
who used UDCA during pregnancy was analysed separately and compared with the data from patients without
medication.
Results: UDCA was well tolerated. Mothers receiving UDCA had ICP diagnosed five weeks earlier than mothers without
medication. At the diagnosis, levels of total BA and ALT were higher in the group using UDCA compared to the group
without medication. Most deliveries were induced and perinatal outcome was good. Apgar scores at 5 min were
significantly lower in UDCA group (p < 0.05), but fetal umbilical artery pH values were similar in both groups (p > 0.05).
There were 30 patients with total BA > 40 μmol/l at diagnosis, 24 with UDCA and 6 without medication and those
deliveries were induced soon after diagnosis. The preterm labour was also more common in these patents (p < 0.05).
Women with preterm babies had significantly early onset pruritus and ICP was diagnosed earlier. Serum ALT and total
BA levels were significantly higher in those pregnancies at diagnosis and also at first control.
Conclusions: Preterm labour was associated in severe ICP (total BA > 40 μmol/l), ALT levels were also significantly
higher and ICP was diagnosed earlier (p < 0.05). Apgar scores were lower in preterm babies (p < 0.05), but umbilical
artery pHvalues were not significantly lower. UDCA was well tolerated by pregnant women. With low-dose UDCA
treatment the obstetric outcome was good. We still recommend careful obstetrical follow-up.
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Background
Intrahepatic cholestasis of pregnancy (ICP) is a condi-
tion of severe itching combined with elevated liver func-
tion tests (elevated fasting serum bile acids or/and
elevated serum transaminases) in previously healthy
pregnant women. It occurs typically during the second
or third trimester of pregnancy and symptoms relief
spontaneously within 2 to 3 weeks after delivery. In
Europe, it affects approximately 10 to 150 per 10000 preg-
nancies [1]. The etiology of ICP is still unknown but its
pathogenesis appears to be related to increased sex hor-
mone synthesis and their altered liver metabolism during
pregnancy [2]. Also environmental factors and genetic
predisposition may be involved [2]. Variations in risk al-
leles for ICP in the two genes primarily responsible for bile
formation have been found. The phosphatidyl choline flop-
pase ABCB4 (MDR3) and the bile salt export pump
ABCB11 have key roles for common variations [3].* Correspondence: titta.joutsiniemi@tyks.fi
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ICP resolves after delivery but it has been associated
with high incidence of fetal complications. It increases the
risk of preterm delivery, meconium excretion, respiratory
distress syndrome and sudden intrauterine death [4].
Glantz et al. (2004) reported a 1–2 % increase in the risk
of spontaneous preterm labour, asphyxial events or meco-
nium staining of the amniotic fluid and/or placenta and
membranes for every additional μmol/L of maternal
serum bile acids [5]. In the same study no increase in ad-
verse outcomes was reported if the maternal serum fasting
bile acids were below 40 μmol/L. The risk of spontaneous
preterm labour is increased in ICP pregnancies (19–60 %)
[6]. Nowadays the majority of preterm deliveries are iatro-
genic reflecting the practice of elective induction of labour
in ICP cases with the aim of reducing the risk of fetal
complications. Patients with ICP are considered as high
risk patients and the timing of delivery should be decided
outweighing the risk of prematurity and ICP complica-
tions. Routinely induction of labour is recommended
for women with ICP after 37 pregnancy week [7]. The
cesarean section rate is not increased by the early in-
duction of labor [8, 9].
The treatment of ICP has mainly been symptomatic be-
cause the pathophysiology is still unresolved. Phenobarbital,
cholestyramine, S-Adenosyl-L-methionine, dexamethasone
and ursodeoxycholic acid have been used [10–13]. It has
been shown that UDCA causes a significant reduction in
liver function tests in ICP [13, 14]. Gurung et al. (2013)
concluded in the Cochrane collaboration that UDCA sig-
nificantly improves pruritus and fewer instances of fetal dis-
tress/asphyxial events were seen in the UDCA groups
when compared with placebo but the difference was not
statistically significant [15]. Bacq et al. [16] found UDCA
have a several benefits for mothers, fetuses as well as for
newborns.
We examined the pregnancy outcome and maternal
liver function tests after using UDCA on Finnish pa-
tients. ICP patients were treated in clinical setting with
UDCA and an observational retrospective study in ICP
and UDCA was done.
Methods
The study was performed in Turku University Central
Hospital between 2000 and 2005. The diagnostics criteria
and the treatment protocol are equal nowadays. During
the study period there were 307 women with ICP. UDCA
was used in 208 of these pregnancies. Thirty-four women
had two pregnancies during this period, so the number of
patients was 273. In this study there were 14 twin preg-
nancies, all together 321 newborns. In the UDCA group
there were 13 twin pregnancies, all together 221 new-
borns. Ninety nine mothers received no medication. In the
group without medication there was one twin pregnancy
and all together 100 newborns.
The diagnosis was made by maternal itching in preg-
nancy with other causes of cholestasis excluded and ele-
vation of total fasting bile acid (>6 μmol/l) and elevation
of serum alanine aminotransferases (>45 U/l).
Patients started UDCA medication according to our
standard protocol usually 450 mg/day. All participating
patients fulfilled the diagnostic criteria, but those who
only had mild symptoms or only slightly elevated liver
function tests did not started UDCA. Also those whose
laboratory values were high and labour induction was
started within a few hours did not have the medication.
A study questionnaire data on maternal age, gravidity,
parity, complications of earlier pregnancies, body mass
index, and use of drugs, medical history, smoking and
heredity of ICP was collected. All follow-up visits in the
antenatal clinic and the dose and side-effects of UDCA
were also recorded. No formal scale was used to show
improvement of pruritus. All patients whose laboratory
values were improved also reported decreased pruritus.
Patients whose laboratory values or symptoms got
worse, labour were induced or dose of UDCA was in-
creased. Eighteen patients used UDCA 600 mg/day and
one patient 900 mg/day. The data of follow-up visits in-
cluded gestational age, blood pressure, urine samples
and the control of biochemical tests including ALT and
total BA. The fetal ultrasound findings and cardiotoco-
graphy (ctg) were also registered.
Obstetric outcome was evaluated. Gestational age at
delivery, induction of labour, duration of labour and ob-
stetrical managements was recorded. Neonatal outcome
(Apgar scores (1, 5 and 15 min), birth weight, pH and
base excess values from umbilical artery blood) was col-
lected. Maternal and neonatal data was analysed and
data of the patients who used UDCA during pregnancy
was analysed separately. Also pregnancies with total bile
acids > 40 μmol/l at diagnosis or preterm birth were ana-
lysed separately.
The statistical analysis was made with T-test, Mann–
Whitney test and Chi-Square test. P-values less than
0.05 were considered statistically significant.
The study protocol was approved by the Ethical
Committee of the University and the Hospital. The in-
formed consent was not obtained, because the study
was retrospective.
Results
Patients’ characteristics are gathered in the Table 1. Age,
parity, smoking, body mass index and ICP heredity were
similar between these two groups. The mean gestational
age at the beginning of pruritus was 33.6 weeks in the
whole group, 32.2 in the UDCA group and 36.8 in the
group without medication (p < 0.05). Mothers receiving
UDCA during pregnancy had ICP diagnosed 5 weeks
earlier than mothers without medication (p < 0.05). In
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most cases without UDCA, the onset of ICP was in the
last weeks of pregnancy and these mothers did not re-
quire treatment, either because the symptoms were mild
or because the pregnancy was terminated. The abdom-
inal ultrasound was made to patients suffering from high
levels of liver enzymes especially increased ALT to ex-
clude other liver pathology. Gall stones were detected by
ultrasonograhpy in 4 % (N = 8) of the mothers using
UDCA and in 1 % (n = 1) in the group without medica-
tion for ICP. None of the patients were operated due to
cholelithiasis during pregnancy.
The medication with UDCA was started for 208 pa-
tients and the mean dose of UDCA was 450 mg/day
(range 150–900). The mean gestational age at the diag-
nosis was 33.3 weeks and at the first control visit
34.8 weeks. Most patients started UCDA medication at
the first visit in the maternal care unit (N = 196) and
their first control was at 34.2 gestational week. Twelve
patients started medication later in the pregnancy be-
cause ICP was mild at the diagnosis. The symptoms got
worse and the liver enzymes were higher later in the
pregnancy and the medication was started. Only 1.4 % of
the patients had side effects from the medication. Two
patients had abdominal pain and one reported nausea.
At the diagnosis levels of total BA and serum ALT were
higher in the group using UDCA compared to the group
without the medication, but only the difference between
the levels of ALT was statistically significant (p < 0.05).
Figs. 1 and 2 represent these values at the diagnosis and at
the visits in the antenatal clinic. Both total bile acid level
and concentrations of ALT begun to decrease after start-
ing the medication (Figs. 3 and 4). The decline of total BA
values between diagnosis and the control visits was statis-
tically significant in UDCA group (P < 0.05). Serum ALT
values begin to decrease significantly after first control
visit (p < 0.05). Also in the group without the medication a
decrease in serum levels of BA acids and ALT was re-
corded probably because the patients with a more severe
ICP delivered already during the first weeks of the study
period and the number of women coming to the last visits
was small and the ICP was mild. However that was not
statistically significant.
Obstetric and neonatal characteristics are presented in
Table 2. Mothers using UDCA delivered on the mean of
37 gestational week and mothers without medication on
the mean of 38 gestational week (p < 0.05). There were
Table 1 Patients’ characteristics comparing ursodeoxycholic acid treatment and no medical treatment in ICP. Values are given as
numbers (%) or mean [SD]
ALL n = 307 No medication n = 99 UDCA n = 208 P
Maternal age (years) 29.6 [5.2] 28.8 [4.6] 29.9 [5.4] NS
Smoking 26 (8 %) 12 (12 %) 14 (7 %) NS
Body mass index 23.5 [4.1] 22.9 [3.7] 23.8 [4.2] NS
Former deliveries (range) 1.0 (0–8) 1.0 (0–8) 0.8 (0–5) NS
ICP in earlier pregnancy 92 (30 %) 27 (27 %) 65 (31 %) NS
Heredity 7 (2 %) 3 (3 %) 4 (2 %) NS
Beginning of itching (wks) 33.6 [3.9] 36.8 [2.5] 32.2 [3.6] P < 0.05
ICP diagnosed (wks) 34.8 [3.5] 38.0 [1.5] 33.3 [3.1] P < 0.05
Bile acid at diagnosis (μmol/l) 19.2 [24.9] 16.7 [26.7] 20.5 [24.0] NS
ALT at diagnosis (U/l) 152.8 [166.1] 96.4 [106.6] 179.2 [181.9] P < 0.05
Abdominal ultrasound 35 (11 %) 4 (4 %) 31 (15 %) p < 0.05




















Fig. 1 Total bile acid (TBA) concentration (μmol/l) with patients with
UDCA (■), all patients (♦) and patients without medication (▲) at
the diagnosis (0) and at visits (1–4) in the antenatal clinic. The statistical
analysis was calculated during two weeks. All patients: Decrease in TBA
levels was statistically significant between at diagnosis and second
antenatal visit and also between first and second antenatal visit
(p< 0.05). UDCA group: Decrease in TBA levels was statistically significant
between at diagnosis and first antenatal visit and between first and
second antenatal visit (p< 0.05)
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more preterm deliveries (<37 weeks) in the group using
UDCA due to severity of ICP (p < 0.05). Most of the de-
liveries were induced and labour induction rate was
higher with UDCA users (p < 0.05). Caesarean section
rate in our hospital during the study period varied
between 13.9 and 17.4 % and in the study cohort the rate
was 15 %. The vacuum extraction rate was 5.8–7.3 % in
the hospital and in this study 5.5 %. The perinatal out-
come was good and there were no perinatal deaths in our
study material. Apgar scores at 5 min were significantly
lower in UDCA group (p < 0.05), but fetal umbilical artery
pH values were similar in both groups (p > 0.05). The rate
of admissions to the neonatal unit was higher for children
in the UDCA group (30 % vs 11 %) mostly due to preterm
labour (Table 3) which was more common in UDCA users
(p < 0.05). Women with preterm babies had significantly
early onset pruritus and ICP was diagnosed earlier. Serum
ALT and total BA were significantly higher in those preg-
nancies at diagnosis and also at first control. Also new-
borns’Apgar scores were significantly lower (p < 0.05), but
umbilical artery pH values were equal.
There were 30 patients with severe ICP (total BA >
40 μmol/l), 24 with UDCA and 6 without medication.
Four patients got increased UDCA dose to prevent pre-
term delivery. Eight patients delivered spontaneously, 22
were induced. The preterm labour was also more common
in these patients (p < 0.05). Almost half of these babies,
fourteen, had a treatment period in NICU.
Discussion
Intrahepatic cholestasis of pregnancy has been associ-
























Fig. 2 Concentration of alanine aminotransferase (U/l) with patients
with UDCA (■), all patients (♦) and patients without medication (▲)
at the diagnosis (0) and at visits (1–4) in the antenatal clinic. The
statistical analysis was calculated during two weeks. All patients and
UDCA group: Decrease in ALT levels was statistically significant
between at diagnosis and second antenatal visit and also between



































Fig. 3 Total bile acid concentrations (μmol/l) in the group using UDCA and in the group without the medication
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intrauterine death. The treatment of ICP has been mainly
symptomatic as no specific treatment exists.
UDCA is hydrophilic bile acid and used for the treat-
ment of various cholestatic disorders. Currently, UDCA
is the most promising treatment for ICP. It is well-
tolerated by mothers and no adverse effects in newborns
have been observed. Palma et al. [17] repoted UDCA im-
proved significantly serum biochemistry in patients with
ICP. This study was followed by three small randomised
controlled trials showing a significant reduction of prur-
itus and liver function tests after using UCDA in ICP
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Fig 4 Plasma alanine aminotransferase concentrations (U/l) in the group using UDCA and in the group without the medication
Table 2 Obstetrics and neonatal outcome. Values are given as numbers (%) or mean [SD]
Characteristic All (n = 307) UDCA (n = 208) No medication (n = 99) P
Time of delivery (weeks) 37.9 [1.6] 37.4 [1.5] 38.9 [1.2] p < 0.05
Preterm delivery (<37 weeks) 57 (19 %) 53 (25 %) 4 (4 %) p < 0.05
Gemini 14 (5 %) 13 (6 %) 1 (1 %) p > 0.05
Induction of the labour 222 (72 %) 143 (69 %) 79 (80 %) p < 0.05
Normal vaginal delivery 245 (80 %) 161 (77 %) 84 (85 %) NS
Children (n = 321) (n = 221) (n = 100)
Female 144 (45 %) 98 (44 %) 46 (46 %) NS
Male 177 (55 %) 123 (56 %) 54 (54 %) NS
Weight 3344 [531] 3262 [553] 3525 [428] p < 0.005
Apgar score (5 min) 8.8 [1.0] 8.7 [1.0] 9.0 [0.9] p < 0.05
Fetal Artery pH 7.28 [0.09] 7.28 [0.09] 7.28 [0.10] NS
Fetal Artery pH < 7.05 2 (1 %) 2 (1 %) - NS
Fetal venous BE, mmol/l −4.1 [3.2] −4.0 [3.2] −4.3 [3.2] NS
Fetal BE < −12 mmol/l 4 (1 %) 3 (1 %) 1 (1 %) NS
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reduced aminotransferase and bilirubin levels in all treated
women and there was a significant reduction of pruritus
and bile acids in women with serum bile acid levels ex-
ceeding 40 μmol/l at inclusion [5]. In recent meta-analysis
UDCA was also effective in reducing pruritus and improv-
ing liver test results in patients with ICP [16]. According
to Cochrane database there is insufficient evidence to indi-
cate many treatment alone or in combination in treating
ICP patients [15]. There is also a new meta-analysis which
includes both non- randomized studies and randomized
controlled trials [20]. According to that study UDCA
treatment should be recommended for women with ICP
and it reduces adverse maternal and fetal outcome [20]. In
our study both total bile acid levels and concentrations of
alanine aminotransferase begun to decrease after starting
the medication. However patients’ total BA values de-
creased significantly after starting the medication and ALT
levels decreased significantly after first control visit.
Mazzella et al. [21] reported no adverse reactions of
high dose UDCA (1.5–2 g/d) and concluded that the
high-dose UDCA treatment appeared to improve both
biochemical and clinical parameters of cholestasis and
seemed to be completely safe for the fetus. Zapata et al.
[22] concluded that UDCA was well tolerated by preg-
nant women and no adverse effects were detected in 26
infants followed up for a mean of 6 years after delivery.
UDCA was beneficial in ICP patients in terms of im-
proving maternal pruritus, liver tests and also the final
outcome of pregnancy. UDCA was also well tolerated
and no adverse side effects were detected neither in
mothers nor newborns followed up for 3 months after
birth. An updated follow-up of 26 of these children with
ages up to 12 years old confirmed a normal growth and
development and a lack of disease events attributable to
UDCA [22]. In earlier studies the dose of UDCA has
varied: Diaferia et al. and Nicastri et al. used 600 mg/
day, Palma et al. and Glantz et al. used a higher dose of
UDCA 1000 mg/day and Mazzella et al. even 2 g/day
[13, 14, 18, 19, 21].
In our study there were more preterm deliveries
(<37 weeks) in the group using UDCA due to the earlier
onset and severity of ICP. The rate of admissions to the
neonatal unit was higher for children in the UDCA group
due to preterm labour. Pregnancies complicated by ICP
had a significantly increased risk for iatrogenic and spon-
taneous preterm delivery (Puljic et al. [23]). Nowadays the
majority of ICP patients’ deliveries are induced preterm
with the aim of reducing the risk of adverse fetal outcome.
One cohort study suggests that induction of labour may
reduce intrauterine fetal death compared with expectantly
management [24]. Rioseco et al. concluded that labour in-
duction in ICP patients was beneficial [6]. Roncaglia [9] et
al. concluded that elective delivery at 37 weeks in addition
to monitoring fetal well-being can significantly reduce the
stillbirth rate without increasing caesarean section rate. In
a recent study of Puljic et al. [23] demonstrated that deliv-
ery at 36 weeks’ gestation reduced the perinatal mortality
risk as compared with expectant management. They con-
cluded timing of delivery has to take into account both the
reduction in stillbirth risk balanced with the morbidities
associated with preterm delivery [23].
However, preterm babies have an increased risk of re-
spiratory distress syndrome (RDS) and the risk is even
higher in elective cesarean section than in induced vagi-
nal delivery [25]. In addition, maternal cholestasis may
predispose the newborn to unexpected respiratory dis-
tress syndrome [26]. Zecca et al. concluded that the inci-
dence of RDS in newborns from cholestatic pregnancies
was twice as high as in the reference population. They
hypothesized that bile acids can produce surfactant de-
pletion in the alveoli [26] so the risks and benefits of
preterm delivery must be considered individually. Also
Bacq et al. concluded in their meta-analysis that UDCA
therapy might benefit fetal outcomes [16]. It reduces
fetal distress and fewer neonates in intensive care unit.
Caesarean section rate in our hospital during the study
period varied between 13.9 and 17.4 % and in the study
cohort the rate was 15 %. Also the vacuum extraction
rate was 5.8–7.3 % in the hospital and in this study
5.5 %. Most deliveries were induced and early term de-
livery did not increase the incidence of caesarean section
or vacuum extraction. Chappell et al. 2012 also reported
planned early termed delivery not to increase caesarean
section rate significantly [8]. In a recent prospective
study of Geenes [27] et al. demonstrated significant in-
creased risks of adverse perinatal outcome in severe ICP,
so close antenatal monitoring of pregnancies affected by
severe ICP is supported.
There were no stillbirths in our study material. Also
other recent investigations show a marked decrease in
fetal complication rates probably due to a greater aware-
ness of the disease, experienced management and treat-
ment [4, 19]. In our department the dose of the UDCA
Table 3 Indications for the new-borns’ treatment of NICU
Indications No medication N = 100 UDCA N = 122 All N = 321
Prematurity 2 (2 %) 25 (11 %) 27 (8 %)
Hypoglycaemia 3 (3 %) 16 (7 %) 19 (6 %)
Infection 4 (4 %) 8 (4 %) 12 (4 %)
Breathing prob.a 1 (1 %) 5 (2 %) 6 (2 %)
Asphyxia - 3 (1 %) 3 (1 %)
Exposure to drugs 1 (1 %) 2 (1 %) 3 (1 %)
Weight gain prob - 2 (1 %) 2 (1 %)
Other - 6 (3 %) 6 (2 %)
11 (11 %) 67 (30 %) 78 (24 %)
aincluding wet lung or RDS
Statistical analysis was not done because of small number of the patients
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is quite low, but the perinatal outcome was good and
maternal side-effects were minimal. We still recommend
close fetal status monitoring in all cases of ICP. Accord-
ing to our study low dose UDCA treatment and induced
delivery are safe and recommended as a treatment with
ICP. Patients without the medication need also close
antenatal surveillance.
Conclusion
Low dose UDCA treatment reduces maternal liver func-
tion tests, is well tolerated by pregnant women and no
fetal or neonatal side effects could be detected. Majority
of the labours were induced. ICP is associated with pre-
term birth.
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